Effect of early dexamethasone on major complications and all-cause mortality in severe burns (DEXA-BURN): study protocol for a multicenter, randomized, placebo-controlled, double-blind trial Authors: Alexandre Bourdiol, Nicolas Bruder, François Dépret, Delphine Flattres, Laurent Flet, June Fortin, Anne-Emmanuelle Gaufichon, Boris Glavnik, Matthieu Jeanne, Alexandra Jobert, Boris Jung, Anne-Claire Lukaszewicz, Noéline Mathelier, Morgane Péré, Xavier Pichon, Hugues Ravaux, Pierre-Joachim Mahé, Karim Asehnoune, the DEXA-BURN study group Published: 2026 ABSTRACT AbstractBackgroundSevere burns lead to intense and prolonged systemic inflammation and high rates of organ failure and major complications such as acute respiratory distress syndrome (ARDS), acute kidney injury (AKI) and mortality. Although corticosteroids have shown benefits in various critical care settings, no adequately powered randomized controlled trial has yet evaluated their effect in burn patients.ObjectivesThe DEXA-BURN trial aims to assess whether early administration of dexamethasone reduces the incidence of major complications (moderate-to-severe ARDS or stage 2–3 AKI) and all-cause mortality in adults with severe burns.MethodsDEXA-BURN is a multicenter, randomized, placebo-controlled, double-blind trial conducted in 10 French intensive care units. Adult patients with ≥ 20% total body surface area (TBSA) burns, admitted within 24 h of injury and requiring mechanical ventilation, will be randomized (1:1) to receive either dexamethasone (0.2 mg/kg/day IV for 5 days) or placebo. Two endpoints are pre-specified and evaluated using a hierarchical testing strategy: (1) major complications within 28 days (moderate-to-severe ARDS or AKI KDIGO stages ≥ 2); and, if statistically significant, (2) all-cause mortality at day 90. Secondary endpoints include nosocomial infections, ventilator-free days, intensive care unit /hospital stay, CRP trajectory, and steroid-related adverse events. A total of 478 patients will be enrolled. Analyses will follow the intention-to-treat and modified intention-to-treat principle.DiscussionThis trial will provide high-quality evidence on the effectiveness and safety of corticosteroid therapy in the acute management of severely burned patients. Findings may inform future guidelines and improve critical care practices for this understudied population with a high risk of mortality.Trial registrationEudraCT: 2024-517708-12-00; ClinicalTrials.gov: NCT06968559. Registered on April 22, 2025.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s13063-026-09869-z.Keywords: Severe burns, Intensive care unit, Dexamethasone Introduction Background and rationale {6a} Burn injuries are among the most devastating forms of trauma, associated with a marked local and systemic inflammatory response as well as a high mortality rate. While this inflammation is a physiological phenomenon that favors the healing of tissues, the overproduction of inflammatory mediators in severe burn patients, closely correlated to the total body surface area burned [1], leads to an exacerbated systemic inflammatory response syndrome (SIRS). In turn, SIRS contributes to an enhanced risk of sepsis, ARDS [2] and organ failures in general such as AKI, most of those occurring within the first week of admission [3]. Despite improvements in clinical care in ICU, outcomes in patients with severe burns remain poor. There is growing evidence from other areas of critical care medicine—such as septic shock [4], community-acquired pneumonia (CAP) [5], and ARDS [6] that low-to-moderate doses of corticosteroid therapy improves clinical outcomes, including time to recovery and mortality. Moreover, low-to-moderate dose of corticosteroids decrease severe complications such as AKIs or the need for mechanical ventilation in major surgery [7]. Severe burn patients lie at the crossroads between critical care and major surgery, yet preliminary data are scarce in this population and result from two case–control studies [8, 9] and one small RCT [10] suggesting that corticosteroids may modulate the excessive inflammatory response and contribute to improved organ function. However, to date, robust prospective randomized studies are lacking in this population. The DEXA-BURN trial was designed to address this critical knowledge gap by assessing the effect of early dexamethasone administration on major complications and mortality in patients with severe burns. Objectives {7} Primary: To evaluate whether early administration of dexamethasone reduces the incidence of major complications (ARDS, AKI) and all-cause mortality in adults with severe burns. Primary: To evaluate whether early administration of dexamethasone reduces the incidence of major complications (ARDS, AKI) and all-cause mortality in adults with severe burns. Secondary: To assess effects on nosocomial infections, ventilator-free days at Day 28, duration of mechanical ventilation, ICU and hospital length of stay, CRP trajectory, and tolerance of dexamethasone. Secondary: To assess effects on nosocomial infections, ventilator-free days at Day 28, duration of mechanical ventilation, ICU and hospital length of stay, CRP trajectory, and tolerance of dexamethasone. Trial design {8} This is a multicenter, randomized, placebo-controlled, double-blind, parallel-group superiority trial conducted in French intensive care burn units. Patients will be randomized in a 1:1 ratio, stratified by presence of smoke inhalation and TBSA > 30%. The intervention period is 5 days, and patients will be followed up until day 90. Methods: participants, interventions, and outcomes Study setting {9} The study will be conducted in 10 specialized intensive care units in France. All centers have extensive experience in clinical trials and follow national and international standards for burn care. The list of study sites is available on Appendix 1. Eligibility criteria {10} Inclusion criteria Age ≥ 18 years Age ≥ 18 years Severe burns ≥ 20% of total body surface area (TBSA) Severe burns ≥ 20% of total body surface area (TBSA) Admission to a participating ICU within 48 h of injury Admission to a participating ICU within 48 h of injury Invasive mechanical ventilation Invasive mechanical ventilation Obtained informed consent (next-of-kin consent or emergency procedure) Obtained informed consent (next-of-kin consent or emergency procedure) Exclusion criteria Known allergy or contraindication to corticosteroids Known allergy or contraindication to corticosteroids Immunosuppressive therapy or chronic corticosteroid use Immunosuppressive therapy or chronic corticosteroid use Pregnancy or breastfeeding Pregnancy or breastfeeding Patient under legal protection Patient under legal protection Moribund state or decision to withhold/withdraw life support Moribund state or decision to withhold/withdraw life support Who will take informed consent? {26a} Due to the critical condition of eligible patients, written consent will be obtained from the patient’s legally authorized representative. If no representative is available, we will apply emergency procedure for deferred consent under French emergency inclusion regulations, with confirmation from representatives as soon as possible. The patient will be informed and his written consent will be obtained as soon as his state allows. Additional consent provisions for collection and use of participant data and biological specimens {26b} No additional biological sampling is planned beyond routine care. No samples will be stored or used for ancillary studies. The participant information sheet explicitly addresses the potential reuse of coded data for future research, restricted to scientific purposes in the fields of critical care and burn medicine. Participants are informed of their right to oppose such reuse through a dedicated transparency portal maintained by the sponsor (CHU de Nantes), updated monthly, which details the mandatory GDPR disclosures for each new project. Any ancillary study using trial data would therefore be governed by this framework, without requiring separate individual notification, in accordance with applicable French regulations (MR-001) and EU Regulation 536/2014. Patient and public involvement The French Burn Survivors Association (Association des Brûlés de France) gave their agreement on the trial objectives and outcome relevance during the design phase of the trial. No direct involvement is planned during the conduct of the study or data analysis, but patient representatives will be informed of the results. Explanation for choice of comparators {6b} To our knowledge, no established standard of care specifically targeting the overwhelming inflammatory response that develops in severely burned patients. A placebo-controlled design was selected to rigorously assess the efficacy of dexamethasone. The placebo consists of 0.9% NaCl and is identical in appearance and volume to the investigational product. Interventions {11a} Eligible patients will be randomized to receive either: Dexamethasone group: 0.2 mg/kg (ideal body weight), once daily IV, for 5 consecutive days (maximum dose: 20 mg/day) Dexamethasone group: 0.2 mg/kg (ideal body weight), once daily IV, for 5 consecutive days (maximum dose: 20 mg/day) Placebo group: volume-matched 0.9% sodium chloride IV, once daily, for 5 consecutive days Placebo group: volume-matched 0.9% sodium chloride IV, once daily, for 5 consecutive days All other aspects of burn care (e.g., fluid resuscitation, antimicrobial therapy, wound care, respiratory support) will follow standard practices at each site, in accordance with national or international guidelines. Criteria for discontinuing or modifying allocated interventions {11b} Study treatment may be discontinued in the event of: Life-threatening adverse reactions suspected to be linked to dexamethasone Life-threatening adverse reactions suspected to be linked to dexamethasone Participant or legal representative withdrawal of consent Participant or legal representative withdrawal of consent Medical decision to withdraw or withhold life support Medical decision to withdraw or withhold life support Strategies to improve adherence to interventions {11c} Administration of the study drug will be managed by ICU clinical staff and documented in the electronic case report form (eCRF). Hospital pharmacy at each site will supervise dose preparation and administration. Relevant concomitant care permitted or prohibited during the trial {11d} Systemic corticosteroids not specified in the protocol are prohibited during the first 5 days post-randomization, unless used as rescue therapy in critical situations. Other treatments are authorized in accordance with the rules for dexamethasone use. Provisions for post-trial care {30} Participants will receive standard care throughout and after the trial period. No additional post-trial care or compensation is planned. Outcomes {12} Primary outcomes Hierarchical primary outcome including: Incidence of major complications within 28 days, defined as:oModerate-to-severe ARDS (Berlin definition) [11]oOr AKI KDIGO stages 2–3 [12] Incidence of major complications within 28 days, defined as:oModerate-to-severe ARDS (Berlin definition) [11]oOr AKI KDIGO stages 2–3 [12] oModerate-to-severe ARDS (Berlin definition) [11] Moderate-to-severe ARDS (Berlin definition) [11] oOr AKI KDIGO stages 2–3 [12] Or AKI KDIGO stages 2–3 [12] All-cause mortality by day 90 All-cause mortality by day 90 Secondary outcomes Incidence of nosocomial infections during ICU stay Incidence of nosocomial infections during ICU stay Number of ventilator-free days at day 28 Number of ventilator-free days at day 28 Duration of invasive mechanical ventilation Duration of invasive mechanical ventilation Length of ICU stay and total hospital stay Length of ICU stay and total hospital stay CRP levels on days 1, 3, 5, and 7 CRP levels on days 1, 3, 5, and 7 Incidence of hyperglycemia or other corticosteroid-related adverse effects Incidence of hyperglycemia or other corticosteroid-related adverse effects Participant timeline {13} Schedule of enrollment, interventions, and assessments {13} See SPIRIT Figure below. SPIRIT Figure of participant’s timeline: Post-randomizationClose-outTIMEPOINTDay 0aDay 1bDay 2Day 3Day 4Day 5Day 7Day 14Day 28*Day 90**Enrollment:Eligibility screenXNext of kin consent or legal representative or emergency procedure1XPregnancy test (if appl.)XRandomizationXIntervention/comparatorDexamethasone 0.2 mg/kg IBWXXXXXOr Normal salineXXXXXAssesments:Previous medical historyXGlasgow coma scaleXRoutine clinical2 examinationXXXXXXXXXSOFA score3XX(X)Routine laboratory test4XXXXXXXXCRPXXXXXAdverse eventsXXXXXXICU outcomes5XXVital statusXXa Randomization must occur within 48 h of injuryb Day 1 begins at the time of first infusion of dexamethasone or placebo. Infusion must begin within 6 h of randomization1 Patient informed consent will be recorded as soon as possible2 Routine clinical examination includes screening for ARDS and staging AKI3 SOFA scores are collected only during ICU stay4 Routine laboratory tests are defined as follows: arterial blood gases, creatinine, urea, bilirubin, hemoglobin, white blood cells count and platelet count5 ICU outcomes refer to most clinical endpoints linked to the primary and secondary objectives including infections, ventilator-free days, antibiotic-free days, ICU length of stay, etc.* D28 or ICU discharge, whichever comes first** Day 90: final visit, vital status and hospital LOS collected over the phone a Randomization must occur within 48 h of injury b Day 1 begins at the time of first infusion of dexamethasone or placebo. Infusion must begin within 6 h of randomization 1 Patient informed consent will be recorded as soon as possible 2 Routine clinical examination includes screening for ARDS and staging AKI 3 SOFA scores are collected only during ICU stay 4 Routine laboratory tests are defined as follows: arterial blood gases, creatinine, urea, bilirubin, hemoglobin, white blood cells count and platelet count 5 ICU outcomes refer to most clinical endpoints linked to the primary and secondary objectives including infections, ventilator-free days, antibiotic-free days, ICU length of stay, etc. * D28 or ICU discharge, whichever comes first ** Day 90: final visit, vital status and hospital LOS collected over the phone Sample size {14} The trial has two co-primary endpoints: (1) major complications defined as KDIGO stage ≥ 2 to 3 AKI or moderate-to-severe ARDS within 28 days and (2) 90-day all-cause mortality. To control the overall type I error rate at the two-sided α level of 0.05, a hierarchical testing strategy was pre-specified. Mortality will be formally tested at the same significance level only if the first test is statistically significant. Under this procedure, the familywise error rate is strongly controlled at α = 0.05. Consequently, no adjustment to the sample size is required for multiplicity: each endpoint is powered individually at 90%, and the sample size is determined by the endpoint requiring the larger sample, resulting in a total sample size of N = 478 patients. We assume that the co-primary endpoint defined by (1) major complications within 28 days and (2) 90-day all-cause mortality will be 15% less frequent in the intervention group. Based on previous works on the study population, we were able to pinpoint a mortality incidence on day 90 of 13% [13], an incidence of KDIGO stage 2 to 3 AKI of 20% [3], an incidence of moderate to severe ARDS of 35% [2] and an incidence of 45% of patients with moderate-to-severe ARDS and/or KDIGO stage 2 to 3. To demonstrate a decrease of major complications and/or mortality of 15%, we thus hypothesize that 434 patients are needed to ensure a power of 90% with an alpha risk of 5% (215 per randomization arm). Assuming 10% non-analyzable patients (death, loss to follow-up or consent withdrawal), 478 patients are needed (239 per randomization arm). There will be no patient replacement. Recruitment {15} All consecutive eligible patients will be included. 10 specialized French intensive burn units will participate in the study. Given the study recruitment period of 36 months, recruitment per center will be less than 1.5 patient/center/month. Most of these centers have recently collaborated to achieve effective recruitment in at least one large French interventional trial (NCT04292054). Moreover, the allowance for co-enrollment in our study may further enhance participant recruitment. Assignment of interventions: allocation Sequence generation {16a} Randomization will be generated prior to trial by a biostatistician using random permuted blocks of variable size and stratified by site, presence of smoke inhalation injury, and TBSA > 30%. The schedule will then be uploaded and locked centrally using a secure web-based system (ennov Clinical) by the data manager, prior to any patient enrollment. Concealment mechanism {16b} Allocation will be concealed using sequentially numbered containers prepared and labeled by the hospital pharmacy. The treatment assignment will remain blinded to the clinical staff, participants, or outcome assessors. Implementation {16c} After verifying eligibility criteria, investigators will log into the electronic randomization system to obtain treatment allocation. Hospital pharmacies will prepare the blinded study drug accordingly. Assignment of interventions: blinding Blinding {17a} The trial will be double-blinded. Participants, clinical staff, investigators, pharmacists, and statisticians will remain blinded to group assignment. Placebo and dexamethasone vials will be indistinguishable in appearance, labeling, and packaging. Procedure for unblinding if needed {17b} Dexamethasone is a commonly used drug and we do not anticipate any need for unblinding partly because there is no antidote available. If toxicity is suspected, the attending physician should contact the coordinating center, where the steering committee will assess and validate the need for unblinding. In case of unblinding because of suspected toxicity, every drug from the same shipment will be destroyed. Data collection and management {19, 18a, 18b, 18c} Study data will be collected via a secure electronic case report form (eCRF) designed for this trial. Data entry will be performed by trained research staff at each site. All protocol-required information must be recorded in the eCRF; source documents must be maintained at the site to support the data entered. Data will be anonymized using a unique participant identification number. The eCRF will include built-in edit checks and logic rules to enhance data quality. Data queries will be resolved in collaboration with the study monitor. Data will be hosted and managed by the Nantes University Hospital’s Clinical Research Unit in compliance with French data protection regulations and the General Data Protection Regulation (GDPR). A detailed data management plan (DMP) will be developed and approved prior to database lock. The DMP will describe data validation, audit trails, coding standards, and database security procedures. Only authorized personnel will have access to the full dataset before the study is completed. Statistical methods Statistical methods for primary and secondary outcomes {20a} All variables will be described globally and by treatment arm. Qualitative variables will be summarized using counts and percentages, while quantitative variables will be described using the minimum, maximum, mean ± standard deviation or median [interquartile range], depending on the distribution assessed by graphical inspection (QQ plot). Analyses will be conducted using data from the modified intention-to-treat (mITT) population. The co-primary outcome will also be analyzed in the intention-to-treat (ITT) population as well as in the per-protocol (PP) population. The criteria for including patients in the mITT and in the PP populations, respectively, are as follows: Intention-to-treat (ITT): All randomized patients Intention-to-treat (ITT): All randomized patients Modified intention-to-treat (mITT): All randomized patients except patients whoWere incorrectly randomized and did not meet major eligibility criteria (e.g., absence of valid informed consent or minor status), for whom no data could be retained or analyzed due to regulatory requirements (GDPR).ORDid not receive any of the interventions (dexamethasone or placebo) Modified intention-to-treat (mITT): All randomized patients except patients whoWere incorrectly randomized and did not meet major eligibility criteria (e.g., absence of valid informed consent or minor status), for whom no data could be retained or analyzed due to regulatory requirements (GDPR).ORDid not receive any of the interventions (dexamethasone or placebo) Were incorrectly randomized and did not meet major eligibility criteria (e.g., absence of valid informed consent or minor status), for whom no data could be retained or analyzed due to regulatory requirements (GDPR).OR Were incorrectly randomized and did not meet major eligibility criteria (e.g., absence of valid informed consent or minor status), for whom no data could be retained or analyzed due to regulatory requirements (GDPR). OR Did not receive any of the interventions (dexamethasone or placebo) Did not receive any of the interventions (dexamethasone or placebo) Per-protocol: All randomized patients except those having one or more major protocol violations defined as:Patients not included in the mITT populationORPatients who were not eligible for randomization according to inclusion/non-inclusion criteriaORPatients who accidentally received the wrong intervention (Dexamethasone or placebo and vice versa)ORPatients who did not receive the first dose within 6 h of randomizationORPatients who did not receive the 5 consecutive doses between Day1 and Day 5ORPatients who received corticosteroids outside the study protocolORPatients for whom the co-primary endpoint was not assessable Per-protocol: All randomized patients except those having one or more major protocol violations defined as:Patients not included in the mITT populationORPatients who were not eligible for randomization according to inclusion/non-inclusion criteriaORPatients who accidentally received the wrong intervention (Dexamethasone or placebo and vice versa)ORPatients who did not receive the first dose within 6 h of randomizationORPatients who did not receive the 5 consecutive doses between Day1 and Day 5ORPatients who received corticosteroids outside the study protocolORPatients for whom the co-primary endpoint was not assessable Patients not included in the mITT populationOR Patients not included in the mITT population OR Patients who were not eligible for randomization according to inclusion/non-inclusion criteriaOR Patients who were not eligible for randomization according to inclusion/non-inclusion criteria OR Patients who accidentally received the wrong intervention (Dexamethasone or placebo and vice versa)OR Patients who accidentally received the wrong intervention (Dexamethasone or placebo and vice versa) OR Patients who did not receive the first dose within 6 h of randomizationOR Patients who did not receive the first dose within 6 h of randomization OR Patients who did not receive the 5 consecutive doses between Day1 and Day 5OR Patients who did not receive the 5 consecutive doses between Day1 and Day 5 OR Patients who received corticosteroids outside the study protocolOR Patients who received corticosteroids outside the study protocol OR Patients for whom the co-primary endpoint was not assessable Patients for whom the co-primary endpoint was not assessable All statistical analyses will take into account stratified randomization. Primary outcome The study has a co-primary endpoint assessed using a hierarchical testing strategy: Incidence of major complications within 28 days, defined as moderate-to-severe ARDS (Berlin definition [11]) or AKI stage 2–3 (KDIGO criteria [12]) Incidence of major complications within 28 days, defined as moderate-to-severe ARDS (Berlin definition [11]) or AKI stage 2–3 (KDIGO criteria [12]) All-cause mortality at day 90 All-cause mortality at day 90 First, we will test the superiority of dexamethasone on major complications within 28 days after randomization (binary qualitative variable: presence or absence of major complications) with the use of mixed effects logistic regression adjusted on stratification factors (smoke inhalation injury and TBSA > 30%) as fixed effects and on center as random effect. Second, the superiority of dexamethasone on all-cause mortality at day 90 will be formally tested only if the first endpoint reaches statistical significance, in accordance with the pre-specified hierarchical testing procedure. All-cause mortality at day 90 will be analyzed with frailty survival models adjusted on stratification factors (smoke inhalation injury and TBSA > 30%) as fixed effects and on center as random effect. Time to death is defined from randomization date to time of death. If no event, a censor will be applied at the last news date or at day 90. A group-dependent Kaplan Meier curve will also be performed. Estimand strategies will be specified for the co-primary hierarchical endpoint. Methods for additional analysis (e.g., subgroup analysis) {20b} Major complications within 28 days Population: Randomized adult severe burn patients admitted to an intensive burn unit and presenting with a burn ≥ 20% of TBSA. Variables: major complications defined as moderate-to-severe ARDS (using Berlin definition criteria) within 28 days or AKI KDIGO 2 to 3 within 28 days. Study intervention: dexamethasone plus standard of care (SOC) versus placebo plus SOC. Population-level summary: difference in the percentages of major complications within 28 days between the two study groups, with corresponding confidence interval (95% CI). Intercurrent events (IE) and their corresponding strategies: Intercurrent events before D28Strategy for addressing intercurrent events· ICU discharge Treatment policy strategy: The observed value is used regardless of ICU discharge.· Death Composite strategy: Death is considered a major complication – treatment failure· Missing data - Study data unavailable for the evaluation of complications- Administrative censoring (e.g. withdrawal of consent, loss to follow-up)Treatment policy strategy: Data will be censored at the date of last evaluation. Missing primary endpoint data will be analyzed by multiple imputation or worst-case clinical scenario (treatment success in arm 2 and treatment failure in arm 1) as a sensitivity analysis.· Study treatment discontinuation- No administration of allocated treatment - Delay in first administration not respected (> 6 hours from randomization)- Premature discontinuation due to toxicity or adverse eventsTreatment policy strategy: The observed outcome is used regardless of treatment discontinuation· Concomitant or additional treatments - Rescue corticosteroid therapy before day 5Treatment policy strategy: The observed outcome is used regardless of additional treatmentsAndHypothetical strategy: All data collected after the administration of additional treatments will be erased and imputed as worst clinical scenario (treatment success in arm 2 and treatment failure in arm 1) as sensitivity analyses. Composite strategy: Death is considered a major complication – treatment failure · Missing data - Study data unavailable for the evaluation of complications - Administrative censoring (e.g. withdrawal of consent, loss to follow-up) Treatment policy strategy: Data will be censored at the date of last evaluation. Missing primary endpoint data will be analyzed by multiple imputation or worst-case clinical scenario (treatment success in arm 2 and treatment failure in arm 1) as a sensitivity analysis. · Study treatment discontinuation - No administration of allocated treatment - Delay in first administration not respected (> 6 hours from randomization) - Premature discontinuation due to toxicity or adverse events · Concomitant or additional treatments - Rescue corticosteroid therapy before day 5 Treatment policy strategy: The observed outcome is used regardless of additional treatments And Hypothetical strategy: All data collected after the administration of additional treatments will be erased and imputed as worst clinical scenario (treatment success in arm 2 and treatment failure in arm 1) as sensitivity analyses. All-cause mortality at D90 Population: Randomized adult severe burn patients admitted to an intensive burn unit and presenting with a burn ≥ 20% of TBSA. Variable: all-cause mortality on Day 90. Study intervention: dexamethasone plus standard of care (SOC) versus placebo plus SOC. Population-level summary: Hazard ratio for all-cause mortality at D90. Intercurrent events (IE) and their corresponding strategies: Intercurrent eventsStrategy for addressing intercurrent events· Missing data - Administrative censoring (e.g. withdrawal of consent, loss to follow-upTreatmentpolicy strategy: Data will be censored at the date of last evaluation.· Study treatment discontinuation- No administration of allocated treatment- Delay in first administration (> 6 hours from randomization)- Premature discontinuation due to toxicity or adverse events- Dexamethasone or any steroids administration as rescue therapy.- Medical decision to withdraw life-sustaining treatmentTreatment policy strategy: Mortality status will be used regardless of whether the intercurrent event occurs.Hypothetical strategy: All data collected after administration of additional treatment will be erased and imputed under the hypothetical scenario in which no patient experienced study treatment discontinuation. · Missing data - Administrative censoring (e.g. withdrawal of consent, loss to follow-up Treatmentpolicy strategy: Data will be censored at the date of last evaluation. · Study treatment discontinuation - No administration of allocated treatment - Delay in first administration (> 6 hours from randomization) - Premature discontinuation due to toxicity or adverse events - Dexamethasone or any steroids administration as rescue therapy. - Medical decision to withdraw life-sustaining treatment Treatment policy strategy: Mortality status will be used regardless of whether the intercurrent event occurs. Hypothetical strategy: All data collected after administration of additional treatment will be erased and imputed under the hypothetical scenario in which no patient experienced study treatment discontinuation. Secondary outcomes Subgroup analyses of the co-primary outcome will be performed according to each of the stratification factors (smoke inhalation injury and TBSA > 30%). Categorical data (e.g., proportion of patients who experience adverse events as pneumonia, infection, KDIGO stages 2 and 3 AKI, RRT, hyperglycemia…) will be analyzed with mixed effects logistic regression adjusted for stratification factors as fixed effects and center as random effect. Results will be expressed as odds ratios with 95% confidence intervals. Longitudinal continuous data will be analyzed with linear mixed models with random effects models adjusted for stratification factors as fixed effects and center to take into account the repeated measurements within patients. Assumptions of normality and homoscedasticity associated with these models will be evaluated. Results will be expressed as mean differences with 95% confidence intervals. Mortality, ICU LOS, and hospital LOS (censored at 90 days) will be analyzed with frailty survival model adjusted for stratification factors as fixed effects and center as random effect. Results will be expressed as hazards ratios with 95% confidence intervals. Antibiotic-free days and invasive ventilator-free days will be analyzed using competitive risks models to take into account the informative censoring and the competing risk due to death, adjusted for stratification factors. The cumulative incidence functions of each competing event (death/extubation or death/discontinuation of antibiotic therapy) will be estimated as well as the area under the curve between the two treatment arms to obtain the difference in Restricted Mean Survival Times (mean survival time of all subjects in the study population followed up to a given time) as well as its 95% confidence interval for inference. Results will be expressed as hazards ratios with 95% confidence intervals. Interim analyses {21b} No interim analysis is planned and no formal criteria will be set for stopping the study. Nevertheless, for safety reasons, a safety analysis will be planned with the Data and Safety Monitoring Board (at 200 patients included). Recommendations for pausing or stopping the study will be made by the DSMB in case of SAEs or SUSAEs. The steering committee will be responsible to continue, hold or stop the study based on the DSMB recommendations. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data {20c} Missing data are not expected for the co-primary outcome and the proportion of missing data for secondary outcomes is expected to be low as well. Missing data will be summarized by treatment arm. If missing data occur for the co-primary outcome, sensitivity analyses will be performed (see Section “Methods for additional analysis (e.g., subgroup analysis) {20b}”) using multiple imputation methods as well as worst-case scenario (missing data considered as the most unfavorable case) and maximum-bias scenario (missing data considered as the most favorable or unfavorable case in the placebo and experimental arms respectively). Plans to give access to the full protocol, participant-level data, and statistical code {31c} Full protocol will be available through publication and appears on ClinicalTrials.gov (NCT06968559). The results of this trial will be submitted for publication in a peer-reviewed medical journal, regardless of the direction or magnitude of the findings. Trials results will also be communicated through scientific conferences and reported on clinical trial registries. The datasets generated and/or analyzed during the current study will not be publicly available at the time of publication of this protocol because recruitment and follow-up are ongoing. After completion of the trial and publication of the primary results, anonymized individual participant data (IPD) underlying the published results, along with the statistical analysis code, will be available upon reasonable request to the corresponding author (subject to approval by the steering committee and in accordance with French and European data protection regulations, including GDPR). Access will be granted for academic research purposes only, following signature of a data-sharing agreement, and for a period of 5 years after publication of the main trial results. Oversight and monitoring Composition of the coordinating center and trial steering committee {5d} The steering committee encompasses the coordinating center team including the coordinating investigator, coordinating center principal investigator, coordinating pharmacist, methodologist, project manager, and clinical research associates. They will coordinate efforts to ensure patient enrollment, issue queries to the other centers, and assist in any way they can to ensure smooth proceedings and the safety of patients enrolled in the study. The steering committee will be responsible to continue, hold, or stop the study based on the recommendations from the data monitoring committee. Only the steering committee may allow unblinding upon request from a treating physician or investigator. The steering committee will be consulted should a request for an ancillary or side study be made. Composition of the data and safety monitoring board, its role and reporting structure {21a} The DSMB is an advisory committee that advises the sponsor and steering committee on the safety of a clinical trial. Its members have expertise in clinical trials (pathology and methodology) and are not involved in the trial. They are appointed for the duration of the trial and commit themselves to their participation as well as to the respect of data confidentiality. The choice of the DSMB members is made in a collegial manner by the coordinator and the sponsor. The DSMB can be called upon by the monitor if a suspected unexpected serious adverse reaction (SUSAR) or a serious adverse event (SAE) presents a particular difficulty in analysis or if a doubt about the benefit/risk balance arises during the trial. The DSMB is an independent group consisting of clinicians or experts that collectively have experience in the management of severe burn patients and/or use of dexamethasone, the use of CS in critical care medicine and specific expertise in the conduct, monitoring and analysis of randomized clinical trials. Adverse events reporting and harms {22} All adverse events (AEs) and SAEs occurring from the time of study drug administration until Day 28 will be recorded. Known adverse effects of corticosteroids, such as hyperglycemia, secondary infections, gastrointestinal bleeding, and neuromuscular complications will be particularly tracked. Monitoring {21a, 23} Monitoring will be conducted by the sponsor or its delegate in accordance with Good Clinical Practice (GCP) and regulatory requirements. A clinical research associate (CRA) will perform on-site visits and remote monitoring to verify: Compliance with the protocol and regulatory requirements Compliance with the protocol and regulatory requirements Accuracy and completeness of the data recorded in the eCRF Accuracy and completeness of the data recorded in the eCRF Proper documentation of informed consent Proper documentation of informed consent Storage and accountability of study drugs Storage and accountability of study drugs Monitoring frequency and intensity will be described in a monitoring plan and adjusted based on site performance and risk assessment. All findings will be documented in monitoring reports. Independent audits may be conducted by the sponsor’s Quality Assurance Unit to assess protocol compliance, trial conduct, and data integrity. Results of audits will remain confidential but may be shared with regulatory authorities upon request. SAEs will be reported to the sponsor within 24 h of awareness. Events will be assessed for severity, seriousness, and relationship to study treatment by the investigator. The sponsor will ensure timely notification to regulatory authorities and ethics committees, in compliance with applicable regulations. An independent Data Safety Monitoring Board (DSMB) will regularly review unblinded safety data (after 100 and 250 patients enrolled). The DSMB may recommend study continuation, modification, or early termination based on predefined stopping rules. Suspected unexpected serious adverse reactions (SUSARs) will be reported according to national pharmacovigilance laws and guidelines. A final safety report will be submitted at study completion. Plans for communication important protocol amendments to relevant parties (e.g., trial participants, ethical committees) {25} Any substantial modifications to the protocol will be submitted by the sponsor to the Agence Nationale de Sécurité du Médicament (ANSM, French National Agency for the Safety of Medicines and Health Products) and the relevant Personal Protection Committee for authorization or information, in accordance with applicable laws and implementing decrees. Once authorized, these amendments will be communicated to all relevant stakeholders, including investigators, clinical site staff, and trial participants (when possible). The protocol will be reissued as an updated, dated version, and patient information and consent forms will be revised and re-signed if necessary, prior to implementation of the changes. Dissemination plans {31a} The results of this trial will be submitted for publication in a peer-reviewed medical journal, regardless of the direction or magnitude of the findings. Trial results will also be communicated through scientific conferences and reported on clinical trial registries. Complete data will be made available upon reasonable request. Authorship and use of professional writers {31b} Authorship will be determined in accordance with ICMJE guidelines which require that each author has (1) made a substantial contribution to the conception or design of the study, or to the acquisition, analysis, or interpretation of data; (2) drafted or critically revised the manuscript for important intellectual content; (3) approved the final version to be published; and (4) agreed to be accountable for all aspects of the work. No professional medical writers will be involved in the preparation of trial publications. Ethics This study has been approved under Regulation (EU) No 536/2014 following a coordinated assessment for the European Medicines Agency (EMA) (Assessment part II), including a favorable opinion from the relevant Ethics Committee (Comité de Protection des Personnes) and the French National Agency for the Safety of Medicines and Health Products (ANSM). All participants or their legally authorized representatives will provide written informed consent as soon as possible, including in case of emergency procedures. The trial will be conducted in compliance with the Declaration of Helsinki, ICH-Good Clinical Practices (GCP) guidelines, and French regulations. Confidentiality of participant data will be strictly maintained. Access to personal data will be limited to authorized research personnel and monitors. Trial status Trial protocol current version is 20250331. It has been approved by the EMA through the ANSM and funded through a PHRC grant by the French Ministry of Health after being peer-reviewed by experts of the field. The trial will be conducted in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and French regulations. The first inclusion could be made as early as October the 10th, 2025. Recruitment should be complete around October the 31 st 2028. Supplementary Information Supplementary Material 1. Acknowledgements The authors wish to thank the CIC immuno-infectiology of Nantes Teaching Hospital for their contributions to the design and development of this study protocol. We acknowledge the support of the Department of Research and Innovation and Nantes Teaching Hospital. We are grateful to the French Ministry of Health for the exhaustive funding of this trial. We are also grateful to the members of the Steering Committee and Data Monitoring Board for their ongoing advice. Special thanks to every investigator, clinician and research assistant from our fellow intensive burn units for their valuable input and support during protocol development as well as their involvement in the proceedings of the trial. Abbreviations Adverse event Acute Kidney Injury Agence Nationale de Sécurité du Médicament et des produits de santé Adverse reaction Acute respiratory distress syndrome Community-acquired pneumonia Commission Nationale de l’Informatique et des Libertés Clinical Research Associate (monitor) Case report form C-reactive protein Corticosteroids Data and Safety Monitoring BOARD Electronic case report form European Medicines Agency Ethical Review Board Good Clinical Practice Ideal body weight Intensive care unit Kidney Disease Improving Global Outcomes Marketing authorization Serious adverse event Serious adverse reaction Suspected unexpected serious adverse reaction Systemic inflammatory response syndrome Total burn surface area Appendix 1 List of participating centers Name of institutionName and address of affiliated departmentCHU de NantesCHU DE NANTES SITE HOTEL DIEU HME1 Place ALEXIS RICORDEAU44093 NANTES CEDEX 1CHU de BordeauxHOPITAL HAUT-LEVEQUE - CHUAvenue DE MAGELLAN33604 PESSAC CEDEXCHU de LilleHÔPITAL ROGER SALENGRO CHU LILLERue EMILE LAINECS 7000159037 LILLE CEDEXCHU de LyonHOPITAL EDOUARD HERRIOT - HCL5 Place D'ARSONVAL69437 LYON CEDEX 03CHR MetzHOPITAL DE MERCY - CHR METZ THIONVILLE1 Allee DU CHATEAUCS 45001 ARS-LAQUENEXY57085 METZ CEDEX 03CHU MontpellierHOPITAL LAPEYRONIE CHU MONTPELLIER371 Avenue DU DOYEN GASTON GIRAUD34295 MONTPELLIER CEDEX 5AP-HPHU SAINT LOUIS SITE LARIBOISIERE APHP2 Rue AMBROISE PARE75475 PARIS CEDEX 10CHU ToulouseHOPITAL DE RANGUEIL CHU TOULOUSE1 Avenue PR JEAN POULHESTSA 5003231059 TOULOUSE CEDEX 9CHU ToursCHRU TROUSSEAU - CHAMBRAYAvenue DE LA REPUBLIQUE37170 CHAMBRAY LES TOURSAP-HMAPHM HOPITAL LA CONCEPTION147 Boulevard Baille13005 MARSEILLE CHU DE NANTES SITE HOTEL DIEU HME 1 Place ALEXIS RICORDEAU44093 NANTES CEDEX 1 HOPITAL HAUT-LEVEQUE - CHU Avenue DE MAGELLAN33604 PESSAC CEDEX HÔPITAL ROGER SALENGRO CHU LILLERue EMILE LAINE CS 7000159037 LILLE CEDEX HOPITAL EDOUARD HERRIOT - HCL 5 Place D'ARSONVAL69437 LYON CEDEX 03 HOPITAL DE MERCY - CHR METZ THIONVILLE 1 Allee DU CHATEAUCS 45001 ARS-LAQUENEXY57085 METZ CEDEX 03 HOPITAL LAPEYRONIE CHU MONTPELLIER 371 Avenue DU DOYEN GASTON GIRAUD34295 MONTPELLIER CEDEX 5 HU SAINT LOUIS SITE LARIBOISIERE APHP 2 Rue AMBROISE PARE75475 PARIS CEDEX 10 HOPITAL DE RANGUEIL CHU TOULOUSE 1 Avenue PR JEAN POULHESTSA 5003231059 TOULOUSE CEDEX 9 CHRU TROUSSEAU - CHAMBRAY Avenue DE LA REPUBLIQUE37170 CHAMBRAY LES TOURS APHM HOPITAL LA CONCEPTION 147 Boulevard Baille13005 MARSEILLE Appendix 2 Study diagram Appendix 3 Definitions of the primary outcome Hierarchical co-primary outcome including: Incidence of major complications within 28 days, defined as:Moderate-to-severe ARDS (Berlin definition) [11]Or AKI KDIGO stages 2–3 [12] Incidence of major complications within 28 days, defined as:Moderate-to-severe ARDS (Berlin definition) [11]Or AKI KDIGO stages 2–3 [12] Moderate-to-severe ARDS (Berlin definition) [11] Moderate-to-severe ARDS (Berlin definition) [11] Or AKI KDIGO stages 2–3 [12] Or AKI KDIGO stages 2–3 [12] All-cause mortality by day 90 All-cause mortality by day 90 All-cause mortality is defined as any death within 90 days occurring after randomization regardless of its cause. Acute respiratory distress syndrome is defined according to the Berlin definition (Table 1 in Appendix 3) Acute kidney injury staging follows KDIGO definition (Table 2 in Appendix 3). Baseline creatinine will be determined from available values within the past year or, failing that, lowest serum creatinine prior to randomization. Table 1The Berlin definition of acute respiratory distress syndrome [11] The Berlin definition of acute respiratory distress syndrome [11] Table 2KDIGO definition of acute kidney injury KDIGO definition of acute kidney injury Authors’ contributions {31b} PJM, AB, and KA conceived the study. AB, KA, and JF led the proposal through funding, protocol development and regulatory authorities. MP is the trial methodologist who led the design and statistical plan. KA, AB, and MP drafted the manuscript. LF is the coordinating pharmacist led the pharmaceutical plan, including drug management and delivery to the centers. AEG, MJ, ACL, BG, BJ, FD, XP, HR, and NB are principal investigators in each associate center and provided assistance in proofreading the trial protocol. DF and NM are CRA in the coordinating center and helped design the protocol and proofread the trial protocol. AJ is our pharmacovigilance expert. Funding {4} DEXA-BURN is funded through a PHRC grant by the French Ministry of Health after being peer-reviewed by experts of the field. Data availability {29} There are no contractual limitations on the availability of data after the study is completed to investigators. Complete data will be made available through reasonable request. Declarations Ethics approval and consent to participate {24} The current study protocol has been approved by the relevant Personal Protection Committee and the French National Agency for the Safety of Medicines and Health Products (ANSM) through the European Medicines Agency (EMA) (2024–517708-12–00) and funded through a PHRC grant by the French Ministry of Health after being peer-reviewed by experts of the field. The trial will be conducted in compliance with the Declaration of Helsinki, ICH-GCP guidelines, and French regulations. Consent for publication {32} Consent forms and related patient information sheet are provided as appendixes. Competing interests {28} The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1. Data Availability Statement There are no contractual limitations on the availability of data after the study is completed to investigators. Complete data will be made available through reasonable request.